

SUPPLEMENTARY TABLE S1. T-CELL RECEPTOR $V\beta$
 PERCENTAGES OF ALTERATION IN AN HIV-1+ DONOR
 FOLLOWING EITHER RESEARCH SCALE OR CLINICAL
 SCALE PROCESS FOR CCR5-ZFN GENOME MODIFICATION
 AND *Ex Vivo* CD4 T-CELL EXPANSION

	<i>Day 0</i>	<i>Research scale UTD</i>	<i>Clinical scale TD</i>
$V\beta$ 1	10.95	10.70	8.74
$V\beta$ 2	24.11	13.66	11.90
$V\beta$ 3	13.44	10.88	10.48
$V\beta$ 4	28.17	10.23	11.60
$V\beta$ 5.1	17.91	13.00	9.75
$V\beta$ 5.2	12.63	11.04	11.27
$V\beta$ 6.1	14.44	11.79	11.26
$V\beta$ 6.4	22.24	8.42	7.99
$V\beta$ 6.5	14.29	11.24	13.00
$V\beta$ 7	12.06	7.26	7.00
$V\beta$ 8	33.06	9.09	6.98
$V\beta$ 9	21.72	20.17	18.91
$V\beta$ 11	12.07	10.28	10.17
$V\beta$ 12.1	9.94	10.34	7.04
$V\beta$ 12.2	11.29	7.56	5.45
$V\beta$ 13.1	12.06	15.35	10.10
$V\beta$ 13.5	10.81 ^a	14.97	13.41
$V\beta$ 14	33.83	3.93	5.43
$V\beta$ 15	22.54	10.04	9.56
$V\beta$ 16	34.74	12.97	10.31
$V\beta$ 17	8.80	5.94	6.41
$V\beta$ 18	11.04	11.13	10.97
$V\beta$ 21	12.20	13.12	12.11
$V\beta$ 22	17.50	16.37	17.35
$V\beta$ 23	22.90	14.99	14.19
$V\beta$ 24	15.57	11.57	13.19

^aLow amount of $V\beta$ transcripts affected reproducibility.
 UTD, untransduced; TD, transduced.